At-Home Cervical Cancer Screening Wand Now Available In All 50 States
The FDA has approved the Teal Wand, the first at‑home cervical cancer screening device, now available nationwide for women ages 25‑65 at average risk. The wand collects a dry cervical sample at home, which is mailed to a lab for HPV and cell analysis, costing $99 with insurance or $249 without. Clinical data showed a 95.2% agreement with clinician‑collected tests, and over 90% of users found the instructions easy. U.S. health agencies have updated guidelines to include self‑collection as a valid screening option.
Ruxolitinib Cream Shows Strong Efficacy and Reassuring Safety in New Analyses
New integrated safety data from 20 trials confirm that ruxolitinib 1.5% cream delivers a low incidence of serious infections, cardiovascular events, thromboembolic events, and malignancies across atopic dermatitis, vitiligo and other inflammatory skin conditions. A phase 3b trial in adults with...
AI-Enabled Virtual HF Care May Help Boost GDMT, Stabilize Weight
A non‑randomized study of the ISHI Health AI‑enabled virtual heart‑failure platform showed significant gains in guideline‑directed medical therapy (GDMT) and improved weight stability among 747 patients across six community cardiology practices. The system collected remote biometric data, generated risk‑graded alerts,...
MedDream to Present AWS-Powered Imaging Viewer at HIMSS
MedDream will demonstrate its cloud‑native, AI‑ready universal DICOM viewer, built on AWS HealthImaging, at HIMSS 2026 in Las Vegas. The solution leverages AWS’s HTJ2K transfer syntax to stream large imaging datasets quickly and securely. It supports radiology, cardiology, ophthalmology, dental...
Newly Added Guidance Documents
The FDA has published a batch of newly added guidance documents, spanning drug exclusivity, post‑approval safety reporting, real‑world data studies, Bayesian trial methods, and patient‑preference research. Ten documents are highlighted, with six in draft form and four finalized, dated between...
Early Matrix Proteins Drive Kidney Fibrosis Dynamics
A new Nature Metabolism study identifies extracellular matrix protein ECM1 as a pivotal early regulator of kidney fibrosis. Global ECM1 knockout mice develop spontaneous fibrosis and premature death, while AAV9‑mediated ECM1 knockdown in fibroblasts markedly lessens fibrotic burden. Mechanistically, ECM1...
Pivot Point Consulting Partners With Microsoft Rural Health Resiliency Program for Dragon Copilot Deployment
Pivot Point Consulting has teamed with Microsoft’s Rural Health Resiliency Program to roll out the Dragon Copilot AI assistant to financially strained rural hospitals. Microsoft is providing a 60% discount off the standard price, while Pivot Point offers free readiness...
Demystifying the Smart Hospital at HIMSS26
Cleveland Clinic CIO Sarah Hatchett will lead a HIMSS26 panel that offers a practical roadmap for building new IT infrastructure and retrofitting existing hospital spaces to accommodate emerging technologies. The session targets health‑system leaders seeking concrete steps to transition toward...
Webinar: The Future Is Collaborative: Transforming Clinical Trials
A MEDSIR‑hosted webinar titled “The Future is Collaborative: Transforming Clinical Trials” examined how collaborative‑initiated trials and investigator‑initiated trials (IITs) are reshaping oncology research. Speakers Dr. Javier Cortés and Dr. Antonio Llombart‑Cussac, both leading breast‑cancer oncologists, discussed their roles in recent...
Bayesian Learning Uncovers Schistosomiasis Multimorbidity Risks
Researchers applied Bayesian machine‑learning to uncover risk factors for hepatosplenic multimorbidity in schistosomiasis. By fusing clinical records, environmental exposure data, and host genetic markers, the model pinpointed predictors such as specific immune‑gene variants and poor sanitation. Its capacity to continuously...
DarcyIQ Integrates with Epic and Athenahealth to Slash Admin Time
DarcyIQ, an AI‑powered revenue acceleration platform from Innovative Solutions, has launched native, HIPAA‑aligned integrations with Epic and athenahealth’s athenaOne using Model Context Protocol. The conversational layer lets clinicians and revenue teams interact with EHR data via natural language, eliminating platform...
MaxLife Technologies Inc. Dba Maxlife - 721453 - 02/20/2026
The FDA issued a warning letter to MaxLife Technologies for false and misleading claims on its website about compounded semaglutide and tirzepatide products. The company labeled the drugs as “generic compounded medication” and implied FDA approval and that MaxLife was...
Synthetic Gene Medicines May Disrupt DNA Repair
Researchers at Karolinska Institutet reported that phosphorothioate antisense oligonucleotides (ASOs) directly bind key DNA‑repair enzymes, forming nuclear condensates that trigger a false DNA‑damage response. The effect was observed at concentrations commonly used in laboratory assays, though clinical doses reach lower...
Mich. FD Rolls Out Peak-Demand EMS Units to Fight Paramedic Burnout
Sterling Heights Fire Department launched a peak‑demand EMS unit staffed by EMTs to handle low‑acuity 911 calls, freeing paramedics for high‑severity incidents. The initiative pairs with a new five‑color dispatch system that prioritizes calls by medical urgency. Since its October...
How New Medicare Rules Will Reshape Cardiac Monitoring and Remote Patient Care
Medicare’s 2026 Physician Fee Schedule introduces outcome‑based payments for cardiac care, rewarding providers who prevent ER visits, readmissions, or accelerate recovery. The rule also replaces the in‑person supervision requirement for the technical component of remote cardiac monitoring with virtual oversight,...
Medbridge Launches Hybrid Pathway to Prevent Workplace MSK Injuries
Medbridge has launched an Occupational Health Pathway within its Medbridge One Care platform, offering a hybrid (live and virtual) model to prevent musculoskeletal (MSK) injuries among industrial workers. The solution targets three high‑risk groups—production and material handlers, maintenance staff, and...
Anterior Integrates Clinical AI Into HealthEdge GuidingCare for Utilization Management
Anterior has embedded its clinician‑led AI reasoning engine into HealthEdge’s GuidingCare platform, which serves more than 70 health plans and 30 million members. The integration places AI directly inside utilization management workflows, eliminating the need for separate tools. Early production data...
'Dismal' Survival Demands Change in Bile Duct Cancer Therapy
An international panel of 147 oncology leaders, including Prof. John Bridgewater, issued a consensus calling for sweeping reforms in the diagnosis, treatment, and research of cholangiocarcinoma (bile duct cancer). The disease remains deadly, with three‑quarters of patients dying within a...
Can Postpartum Depression Start Months After Birth? Experts Explain
Postpartum depression (PPD) can surface months after birth, with research showing onset as late as 12 months postpartum. While the DSM‑5 limits PPD to the first four weeks, clinicians often treat any depression arising within the first year as postpartum‑related....
Nine Companies Advancing Biotech in Philadelphia
Philadelphia’s biotech ecosystem, long known for CAR‑T breakthroughs, is diversifying into obesity, metabolic disease, gene editing, and solid‑tumor immunotherapies. Nine local companies illustrate this shift, from Alveus Therapeutics’ $197 million Series A obesity program to Cabaletta Bio’s autologous CD19 CAR‑T for autoimmune...
Promises And Pitfalls Of Multi-Cancer Diagnostic Tests
Multi‑cancer early detection (MCED) tests analyze blood, urine or saliva for tumor‑derived DNA, RNA or proteins, promising a single‑sample screen for dozens of cancers. While early‑stage detection could complement established organ‑specific programs, sensitivity varies widely, with some cancers identified in...
ZohoDay 2026 - How Newcross Healthcare Builds AI Apps on a Governed Platform - While Keeping AI Hype at Bay
At ZohoDay 2026, Newcross Healthcare showcased how it built a mission‑critical care‑management application on Zoho’s governed platform, unifying CRM, finance, workforce and analytics. By leveraging Zoho Creator, the team delivered a fully integrated solution in six months, cutting licensing costs...
Key Biosimilars Events of February 2026
February 2026 saw a surge of biosimilar activity, with key regulatory approvals for products such as Sandoz Enzeevu (Eylea), Accord Filkri (Neupogen), and STADA Gotenfia (Simponi) across the US, Canada and the EU. Companies forged new licensing and commercialization deals that extend biosimilar...
Quell Takes New Treg Into Clinic After Transplant Study Halt
Quell Therapeutics has launched the phase 1/2 CHILL trial of its autologous CAR‑Treg therapy QEL‑005 in rheumatoid arthritis and systemic sclerosis, after pausing the liver‑transplant program QEL‑001. The multi‑center study will enroll patients in the UK, Germany and Spain, with read‑out...
![Balancing the Role of Physicians and AI [Video]](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://medcitynews.com/wp-content/uploads/sites/7/2026/03/Smarter-Technologies_2.00_00_19_17-1024x576.png)
Balancing the Role of Physicians and AI [Video]
At the ViVE conference, Smarter Technologies’ chief medical officer Ruben Amarasingham highlighted the firm’s AI strategy aimed at improving data accuracy while easing physicians’ documentation load. He cited positive customer feedback that the platform reduces administrative burden and delivers clear...
Cigna CEO David Cordani To Retire And Be Replaced By Internal Choice
Cigna announced that long‑time CEO David Cordani will retire on July 1, 2026, and be succeeded by internal candidate Brian Evanko, the current president and chief operating officer. Cordani, who will remain board chair, has led the firm for 17 years,...
Lynk Pharmaceuticals Reports Topline P-III Trial Data on Zemprocitinib in Atopic Dermatitis
Lynk Pharmaceuticals announced topline Phase III data for its oral JAK inhibitor zemprocitinib in 356 patients with moderate‑to‑severe atopic dermatitis. Both the 12 mg and 24 mg doses met the co‑primary endpoints at week 16, delivering 38‑46 percentage‑point improvements in EASI‑75 and roughly 30 percentage‑point gains...
Animal Drugs: Strengthening Federal Incentives Could Help Address Unmet Animal Health Needs
The GAO report reveals that, despite a conditional approval pathway introduced in 2004 and expanded in 2018, FDA‑approved animal drugs for minor species and niche uses remain scarce. From FY2018 through FY2025, only 13 drugs received conditional approval, all targeting...
STAT+: FDA Is ‘Not Convinced’ UniQure’s Huntington’s Therapy Has Benefit, Senior Official Says
The FDA concluded that UniQure’s experimental gene therapy for Huntington’s disease has not demonstrated therapeutic benefit based on existing clinical data. Reviewers said they are not persuaded by the evidence, prompting the agency to block the company from submitting a...
Exclusive: Anti-Ageing Skin Care Conference Keynote Reframes Skin Ageing as Biodesynchronosis
The anti‑ageing skin‑care conference introduced the concept of biodesynchronosis, framing skin ageing as a loss of regulatory coordination rather than merely chronological time. Speakers argued that traditional markers like wrinkles miss upstream failures, and that recovery speed after stress better...
Senate Bill Would Extend Burial Benefits for Veterans Who Receive Hospice Care
Senators John Boozman (R‑AZ) and Gary Peters (D‑MI) have introduced a bipartisan bill to extend Veterans Affairs burial benefits to veterans who die in hospice or other non‑VA health settings. The legislation builds on the 2023 Dole Act expansion, which...
CIOs Agree Variability the Enemy of Large-Scale IT Shops
At a ViVE conference, CIOs from Christus Health, SSM Health and HCA Healthcare warned that variability, not scale, is the primary cost driver for large health systems. They highlighted governance gaps that allow endless project approvals but few rejections, leading...
This Startup Wants To Use Mini Robots To Treat Alzheimer's
Jacksonville‑based startup MMI is preparing the first U.S. microrobotic surgeries to treat Alzheimer’s by clearing lymphatic drainage pathways in the neck. The FDA granted clearance for an initial safety cohort of 15 patients, with five slated for the first procedure...
Innovent Receives the NMPA Approval for Jaypirca to Treat R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Innovent’s pirtobrutinib, marketed as Jaypirca, received Chinese NMPA approval for adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have undergone at least one prior therapy, including a BTK inhibitor. The decision follows the phase‑III BRUIN CLL‑321 trial,...
CMS Extends Deadline for MFN Pricing Pilot Scheme
The U.S. Centers for Medicare & Medicaid Services (CMS) has pushed back the deadline for manufacturers to join its GENEROUS pilot, extending the initial cut‑off to April 30 while keeping the final deadline at June 30. The voluntary program applies a Most‑Favoured...
Merck and Eisai Present P-III (LITESPARK-011) Trial Data on Welireg + Lenvima in Advanced Renal Cell Carcinoma (RCC) at ASCO...
Merck and Eisai disclosed Phase III LITESPARK-011 results showing that the oral combination of Welireg (belzutifan) and Lenvima (lenvatinib) outperformed cabozantinib in 747 patients with advanced renal cell carcinoma who progressed after anti‑PD‑1/PD‑L1 therapy. At a median follow‑up of 29...
Whitepaper: Digital PSA Surveillance: Using Remote Monitoring for Stable Cancer to Avoid Unnecessary Attendances and Optimise Clinical Capacity
Isla Health’s new whitepaper outlines how NHS trusts can digitise PSA surveillance to cut unnecessary urology follow‑ups. By automating data capture, trusts can process patients 87% faster and slash administrative work by up to 80%, freeing clinical nurse specialists for...
Dermatology Trials by the Numbers: Key Trends and Benchmarks for 2026
Dermatology research is booming, with more than 16,000 trials completed, ongoing, or planned by the end of 2025. The Asia‑Pacific region now hosts roughly 8,000 studies, a five‑fold increase over the past decade, matching North America and Europe combined. Low...
East Cheshire Shares Five Aims for 2026 and Beyond Following EPR Rollout
East Cheshire NHS Trust announced five strategic aims for 2026 following a smoother‑than‑expected Meditech EPR go‑live in June 2025. The plan includes a major system upgrade in March, digitising the top 50 high‑priority clinical documents, and expanding internal referral orders...
Few U.S. Doctors Have Seen Measles in Person. That’s a Problem.
In January, twin brothers with measles were treated at Mission Hospital in Asheville, North Carolina, but staff failed to isolate them for over four hours, exposing at least 26 other patients. A CMS investigation placed the hospital in Immediate Jeopardy,...
Clinically‐Relevant Static Magnetic Field Induces Release of Encapsulated Molecules From Magnetoliposomes
Researchers demonstrated that a clinically‑available 1.5 T static magnetic field can trigger the release of encapsulated molecules from magnetoliposomes (MLs). The study used citric‑acid‑stabilized Fe₃O₄ nanoparticles, with and without a chitosan coating, and monitored structural changes via SAXS and DLS. Fluorescence...
Designing Telehealth for Every Age: What Providers Need to Know About Serving Older Adults
Telehealth’s rapid expansion has left older adults behind because most platforms ignore age‑related cognitive, sensory, and usability challenges. Studies show that while over half of seniors are interested in video visits, only a third feel comfortable using them, highlighting a...
Navigating the FDA After the Storm To Advance Drug Candidates
After a wave of senior departures and a 3,500‑position cut, the FDA entered 2026 with a largely inexperienced workforce, raising uncertainty for drug developers. The agency’s new AI guidance, released in January, outlines best practices but emphasizes human oversight and...
60% Of Older Adults Prefer At-Home Care If Their Needs Increase
A Pew Research survey of 2,582 U.S. adults aged 65 and older finds that 60% would rather stay at home with a caregiver if they can no longer live independently, while only 18% prefer moving to an assisted‑living community. Preference...
Repeal Of Motorcycle Helmet Laws Are Dangerous And Expensive
A University of Michigan study examined the impact of Michigan’s 2022 repeal of its universal motorcycle‑helmet law. Researchers found hospital costs rose by $5,785 per injured rider—a 26% increase—adding more than $4.5 million in annual expenses, or $6.4 million when adjusted to...
FDA Clears Ultrasound AI Tool for Accurate Delivery-Date Prediction
The U.S. Food and Drug Administration granted De Novo clearance to Ultrasound AI’s Delivery Date AI, a cloud‑based software‑as‑a‑medical‑device that predicts a pregnant woman's delivery date using only standard ultrasound images. The model was trained on more than one million...
Where Are the Doctors? Patients Leading the Conversation on TikTok About Hidradenitis Suppurativa in Skin of Color
A new JMIR Dermatology study finds TikTok is the primary education source for patients with hidradenitis suppurativa (HS) in skin of color. Researchers analyzed 50 videos and discovered that nearly half were patient‑generated, while only about 20% featured dermatologists. Physician‑authored...
Cryoport Inc (CYRX) Q4 2025 Earnings Call Transcript
CVRx reported fourth‑quarter 2025 revenue of $16 million, a modest 4% year‑over‑year increase, while gross margin improved to 86% driven by higher selling prices and manufacturing efficiencies. Net loss widened to $11.9 million as SG&A and R&D expenses outpaced revenue growth, but...
Evolus Inc (EOLS) Q4 2025 Earnings Call Transcript
Evolus Inc. reported fourth‑quarter 2025 net revenue of $90.3 million, a 14% year‑over‑year increase, and full‑year revenue of $297.2 million, marking a sixth consecutive double‑digit growth year. Jeuveau drove the bulk of sales, achieving over 14% U.S. market share, while the newly...
Neuropace Inc (NPCE) Q4 2025 Earnings Call Transcript
NeuroPace reported fourth‑quarter 2025 revenue of $26.6 million, a 24% year‑over‑year increase driven primarily by a 26% rise in RNS system sales to $22.4 million. Gross margins improved to 77.4% overall and 80.5% for the RNS product, while operating expenses grew slower...